LBP and COVID-19: In addition, bioinformatics analysis showed that abnormalities in the IL-17 signaling pathway may increase the risk of herpes zoster in COVID-19 (47).Combined with drug target prediction tools and PPI network, Cytoscape screened out the core targets of Paxlovid against LUAD/COVID-19, including CXCL2, CCL2, IL12B, CSF3, LBP, IL6, CXCL10.